What is the nature of the 8,861-share award reported for XRAY executive Andrea L. Frohning?

The 8,861 shares represent a grant or award acquisition of DENTSPLY SIRONA common stock, not an open-market purchase. The Form 4 shows a transaction price of zero per share, indicating an equity-based compensation award to the SVP and CHRO rather than a cash-funded trade.

Dentsply Sirona (XRAY) SVP awarded 8,861 common shares in Form 4

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

DENTSPLY SIRONA Inc. reported that executive Andrea L. Frohning, SVP and CHRO, acquired 8,861 shares of common stock as a stock award. The shares were received at no cash cost per share, increasing her directly held position to 42,863.252 shares.

According to a footnote, this relates to performance-based restricted stock units granted on March 3, 2023. The issuer’s Compensation Committee certified that the performance criteria were met and 1,478 PRSUs were attained on March 2, 2026, with those PRSUs scheduled to vest into shares on March 3, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Frohning Andrea L.

Role SVP, CHRO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,861	$0.00	--

Holdings After Transaction: Common Stock — 42,863.252 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/03/2026 - 04:59 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frohning Andrea L.

(Last)

(First)

(Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE

28277

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, CHRO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		A		8,861⁽¹⁾	A	$0	42,863.252	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units ("PRSUs"). Each PRSU represents a contingent right to receive a share of the Issuer's Common Stock upon settlement. The Compensation Committee of the Issuer's Board of Directors certifies attainment based on the Issuer's satisfaction of certain performance criteria. The performance criteria were met and 1,478 PRSUs were certified as attained on March 2, 2026. The PRSUs vest and become shares of the Issuer's Common Stock on March 3, 2026.

	/s/ Jessica Nielsen Causey, Attorney-in-Fact for Andrea Frohning	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did DENTSPLY SIRONA (XRAY) report for Andrea L. Frohning?

DENTSPLY SIRONA reported that SVP and CHRO Andrea L. Frohning acquired 8,861 common shares through a stock award. The award carried a zero purchase price per share and raised her directly owned stake to 42,863.252 shares of the company’s common stock.

How many DENTSPLY SIRONA (XRAY) shares does Andrea L. Frohning own after this Form 4?

After the reported award, Andrea L. Frohning directly holds 42,863.252 DENTSPLY SIRONA common shares. This total reflects the addition of 8,861 shares acquired at no cash cost, as disclosed in the Form 4 insider transaction filing for the senior executive.

What performance-based restricted stock units are mentioned in the DENTSPLY SIRONA (XRAY) Form 4 footnote?

The footnote explains that performance-based restricted stock units were granted on March 3, 2023. Each PRSU represents a contingent right to one common share. The Compensation Committee certified that 1,478 PRSUs were attained on March 2, 2026, with vesting into shares scheduled for March 3, 2026.

Did Andrea L. Frohning pay cash for the DENTSPLY SIRONA (XRAY) shares reported in this Form 4?

No cash outlay is indicated for the 8,861 shares, as the transaction price per share is reported as 0.0000. This confirms the shares were received as an equity award, consistent with compensation-related grants rather than a traditional open-market stock purchase.